Table 1.
Cohort Demographics
| Variable | Level | N = 827 (%) |
|---|---|---|
| Gender | Female | 280 (33.9) |
| Male | 547 (66.1) | |
| Dural-based metastases | No | 769 (93.0) |
| Yes | 49 (5.9) | |
| Unknown | 9 (1.1) | |
| Intraventricular metastases | No | 804 (97.2) |
| Yes | 23 (2.8) | |
| Tumors bordering ventricle/cistern | 0 | 635 (76.8) |
| 1 | 147 (17.8) | |
| 2 | 28 (3.4) | |
| >2 | 17 (2.1) | |
| Location of brain metastases | Supratentorial | 665 (80.4) |
| Infratentorial | 38 (4.6) | |
| Both | 124 (15.0) | |
| Chemotherapy before initial MBM diagnosis | No | 646 (78.1) |
| Yes | 181 (21.9) | |
| Chemotherapy after initial MBM diagnosis | No | 435 (52.6) |
| Yes | 392 (47.4) | |
| Immune therapy before initial MBM diagnosis | No | 485 (58.6) |
| Yes | 342 (41.4) | |
| Immune therapy after initial MBM diagnosis | No | 437 (52.8) |
| Yes | 390 (47.2) | |
| Craniotomy for tumor resection | No | 452 (54.7) |
| Yes | 375 (45.3) | |
| Ventricular entry during surgery | No | 332 (89.5) |
| Yes | 39 (10.5) | |
| Unknown/Not applicable | 456 | |
| First-line radiation | WBRT | 146 (17.7) |
| SRS/FSRT | 470 (56.8) | |
| WBRT±SRS | 44 (5.3) | |
| None/Unknown | 167 (20.2) | |
| Development of LMD | No | 754 (91.2) |
| Yes | 73 (8.8) | |
| Survival time after LMD diagnosis (months) | Minimum | 0.2 |
| Maximum | 38.5 | |
| Mean | 4.1 | |
| Median | 2.1 | |
| SD | 6.4 | |
| Follow-up time (months) | Minimum | 3.0 |
| Maximum | 217 | |
| Mean | 22.4 | |
| Median | 12.6 | |
| SD | 25.6 |